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Abstract
We sought to describe patterns of treatment and clini-
cal outcome in patients with HER2-positive advanced 
breast cancer progressing on trastuzumab-based ther-
apy. One hundred eighty-four consecutive HER2-posi-
tive advanced breast cancer patients received trastu-
zumab-based therapy between September 1999 and 
September 2004. Patients were followed up until death 
or May 2005. For patients progressing on trastuzumab-
based therapy, we calculated the response rate (RR) to 
the first post-progression treatment, overall survival 
(OS) from the first administration of trastuzumab, time 
to second progression (TT-SP), and post-progression 
survival (PPS), according to treatment. At the time of 
this analysis, 132 patients had progressed on trastu-
zumab-based therapy, and 89 had died. Of the progress-
ing patients, 21 experienced rapid progression and could 
not receive additional anticancer treatments; 40 patients 
continued trastuzumab either alone (12 patients with 
isolated central nervous system progression), with che-
motherapy (23 patients), or with endocrine therapy (5 
patients); and 71 stopped trastuzumab and received 
chemotherapy (61 patients) or endocrine therapy 
(10 patients) as the first post-progression treatment. 
Excluding patients with rapid progression, clinical out-
comes were similar whether trastuzumab was continued 
or not, in terms of RR (18% and 27%, respectively), OS 
(31 and 30 months, respectively), TT-SP (6 and 7 months, 
respectively), and PPS (21 and 19 months, respectively). 
The clinical outcome of patients with HER2-positive 
advanced breast cancer progressing during trastu-
zumab-based therapy might not be influenced by con-
tinuing trastuzumab. The optimal therapeutic strategy 
in this setting of patients needs evaluation in random-
ized trials. The Oncologist 2006;11:318–324
Introduction
Trastuzumab, a monoclonal antibody directed against 
HER2, the product of the c-erbB-2 proto-oncogene, has rep-
resented a major improvement in the treatment of the subset 
of 20%–30% human breast cancers with this genetic abnor-
mality. Randomized studies in the metastatic and adjuvant 
settings have shown that the addition of trastuzumab to che-
motherapy results in significant improvements in clinical 
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outcomes, including overall survival [1–4]. Yet, because 
of its nature of targeted therapy and the uncertainties on its 
exact mechanism of action, several issues, which have rele-
vant clinical and pharmacoeconomic implications, remain 
unresolved. Trastuzumab as a single agent has a response 
rate that peaks at around 35% in appropriately selected 
metastatic breast cancer patients [5]. When added to che-
motherapy in the same setting, the response rate is almost 
double, and survival is longer than with chemotherapy 
alone [1, 2]. Unfortunately, most of the metastatic patients, 
including those with an impressive tumor response, develop 
disease progression during treatment. Preclinical experi-
ments showed that trastuzumab exerts a cytostatic, rather 
than a cytotoxic, action on HER2-positive breast cancer 
cells [6]. Its withdrawal results in cancer growth, which can 
be suppressed by reintroducing the monoclonal antibody. 
On the basis of these observations and on the results of the 
early clinical trials, there is consensus that, in a responding 
patient with metastatic breast cancer, trastuzumab should 
be continued at least until tumor progression. In contrast, 
whether to stop or continue trastuzumab in a patient show-
ing disease progression while on treatment is a subject of 
controversy. Preclinical data demonstrated that trastu-
zumab has additive or even synergistic effects with most of 
the cytostatic agents that are active in the treatment of breast 
cancer, including taxanes, vinorelbine, platinum salts, and 
others [7, 8]. These data, coupled with the tolerability of 
trastuzumab, have suggested to clinicians that continu-
ing trastuzumab and changing the companion cytostatic 
agent could be a reasonable option in patients progressing 
on trastuzumab-based therapy. A few retrospective analy-
ses in patients with HER2-positive advanced breast cancer 
showed encouraging response rates and survival when, 
upon disease progression, trastuzumab was continued 
and patients received further chemotherapy [9–11]. One 
obvious flaw of these reports is that patients discontinu-
ing trastuzumab because of serious trastuzumab-related 
toxicity, or those experiencing rapid disease progression 
during the initial trastuzumab-based therapy and unable 
to receive further anticancer therapy, were not considered. 
Therefore, an encouraging clinical outcome might be the 
result of a selection bias. Indeed, in a follow-up analysis 
of 42 patients enrolled in a phase II trial of docetaxel and 
trastuzumab [12, 13], we observed that progressing patients 
who could receive additional anticancer treatments without 
trastuzumab had clinical outcomes that were in the range of 
patients continuing trastuzumab beyond disease progres-
sion. In the absence of data from a randomized trial, our aim 
was to describe patterns of disease progression and treat-
ment in patients with HER2-positive advanced breast can-
cer receiving trastuzumab-based therapy.
Patients and Methods 
We collected information on 184 consecutive women 
with HER2-positive advanced breast cancer who received 
trastuzumab-based therapy between September 1999 and 
September 2004 at seven Italian institutions. Patient char-
acteristics are summarized in Table 1. Data were entered 
into a database, and follow-up information was updated as 
of May 2005. Data on the initial trastuzumab-based regi-
mens are summarized in Table 2. Sixty patients took part 
in phase II clinical trials evaluating trastuzumab in asso-
ciation with docetaxel (42 patients), with docetaxel and 
epirubicin (14 patients), and with docetaxel and liposomal 
doxorubicin (4 patients), whereas the other 124 received 
trastuzumab-based therapy outside clinical trials. Response 
rates to the initial trastuzumab-based regimen (complete 
response [CR] plus partial response [PR]) were 55.4% (95% 
confidence interval [CI], 48.2%–62.4%), 57.4% (95% CI, 
49.4%–65.1%), and 71.0% (95% CI, 59.4%–80.4%) in the 
overall population, in patients with strong immunohisto-
chemical (IHC) positivity for HER2 (3+), and in patients 
with HER2-positive tumors  by fluorescence in situ hybrid-
ization (FISH), respectively. The median time to progres-
sion was 9.0 months (95% CI, 7.4–11.5 months). Details 
of the first post-progression treatment were required, but 
investigators were invited to provide information on any 
further anticancer treatment the patient received until death 
or the end of follow-up.
Table 1. Patient characteristics
Variable Value
Median age in years (range) 53 (29–80)
Median disease-free intervala 21 (0–752)
HER2 status
 IHC 3+ 148 (80%)
 IHC 2+ 18 (10%)
 IHC positive NAS 18 (10%)
ER- and/or PgR-positive 93 (50%)
Prior exposure to anthracycline 128 (70%)
Prior exposure to taxane 67 (36%)
Up-front metastatic presentation 38 (21%)
Received T-based treatment as first-line 
therapy for metastases
119 (66%)
Single metastatic site 66 (36%)
Visceral involvement (liver and lung) 137 (74%)
aMonths from surgery to the first evidence of recurrent 
disease.
Abbreviations: ER, estrogen receptor; FISH, fluorescence in 
situ hybridization; IHC, immunohistochemistry; NAS, Not 
otherwise specified; PgR, progesterone receptor; T, trastu-
zumab.
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Statistical Analyses
In patients who progressed during the initial trastuzumab-
based regimen, we studied the following outcomes: (a) 
response rate (RR) to the first post-progression treatment 
(CR plus PR), as reported by each investigator at each site; 
(b) overall survival (OS), which was calculated from the 
day of the first administration of trastuzumab-based ther-
apy to the documented date of death; (c) time-to-second 
tumor progression (TT-SP), which was calculated from the 
date of the first progression on trastuzumab-based therapy 
to the date of documented further tumor progression, or 
death of the patient in the absence of tumor progression; 
(d) post-progression survival (PPS), which was calculated 
from the date of the first progression on trastuzumab-based 
therapy to the date of the documented death of the patient. 
Patients alive were censored at the date of the last follow-up 
contact. Survival analyses were conducted by the Kaplan-
Meier method. Because of the retrospective nature of the 
analysis and the descriptive aim of this report, we did not 
perform statistical comparisons of the clinical outcomes in 
different patient subsets. 
Results
Figure 1 shows the flowchart of events and patterns of 
treatment for the entire group of 184 patients. The median 
follow-up for all the patients was 17 months (range, 1–66 
months). Eighteen patients (10%) discontinued trastu-
zumab in the absence of tumor progression either because 
of unacceptable toxicity or the patient’s or treating physi-
cian’s decision (median duration of trastuzumab therapy, 
7 weeks; range, 1–155 weeks). A total of 132 patients pro-
gressed while on the initial trastuzumab-based regimen and 
89 died of tumor progression. Notably, a subset of 21 (16%) 
patients experienced rapid progression and could receive 
only supportive care until death. Upon first progression, 
trastuzumab was continued in 40 and stopped in 71 patients 
(Table 3 and Table 4). In the former group, 12 patients with 
isolated central nervous system (CNS) progression received 
radiotherapy and continued trastuzumab alone. The other 
28 received trastuzumab combined with chemotherapy 
(23 patients) or endocrine therapy (5 patients). In the latter 
group, 61 women received chemotherapy and 10 received 
Table 2. Summary of initial trastuzumab-based regimens
Treatment 
No. of 
patients %
Docetaxel, 75 mg/m2 q3w, plus T 78 42
Vinorelbine, 25/30 mg/m2 weekly, plus T 43 23
Docetaxel, 75 mg/m2, plus epirubicin, 75 
mg/m2, q3w plus T
14 8
Paclitaxel, 80/90 mg/m2 weekly, plus T 12 6
Paclitaxel, 175 mg/m2 q3w, plus T 4 2
5-FU CI plus vinorelbine plus T 7 4
5-FU CI plus T 3 2
Paclitaxel, 80/90 mg/m2 weekly, plus car-
boplatin, AUC 2 weekly, plus T
4 2
Docetaxel, 75 mg/m2, plus liposomal 
doxorubicin, 50 mg/m2 q3w, plus T
4 2
Other regimens plus T 8 4
Trastuzumab alone 4 2
Unknown 3 2
Abbreviations: 5-FU, 5-fluorouracil; AUC, area under the 
concentration-versus-time curve; CI, continuous infusion; 
q3w, every 3 weeks; T, trastuzumab.
Figure 1. Flowchart of events.
Abbreviation: T, trastuzumab.
Table 3. Summary of first post-progression treatments: 
patients continuing trastuzumab
Treatment (in addition to trastuzumab) n
Chemotherapy 23
 Vinorelbine 17
 Taxanes (docetaxel or paclitaxel) 4
 Liposomal doxorubicin 1
 Capecitabine 1
Endocrine therapy 5
 Letrozole 3
 Tamoxifen 2
Trastuzumab alone 12
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endocrine therapy as the first post-progression treatment. 
Table 5 and Figure 2 summarize the clinical outcomes of 
patients according to the pattern of post-progression treat-
ment. Women with isolated CNS progression were excluded 
from the calculation of RR. Survival outcomes were similar 
when we focused on patients receiving chemotherapy alone 
or chemotherapy with trastuzumab beyond progression, 
thus excluding patients who received endocrine therapy or 
those with isolated CNS metastases who received trastu-
zumab alone (data not shown). We conducted additional 
exploratory analyses for the subsets of patients with HER2-
overexpressing (HER2 3+ by IHC) and HER2-amplified 
tumors, with results that were similar to those of the whole 
group (data not shown). Additionally, we evaluated differ-
ences in clinical characteristics of women continuing or 
stopping trastuzumab upon disease progression and found 
that the former were significantly younger (median age, 48 
vs. 55 years; p = .05), were more likely to have responded 
(CR or PR) to the initial trastuzumab-based regimen (67% 
vs. 52%; p = .09), and were more likely to have experienced 
isolated CNS progression during the initial trastuzumab-
based regimen (27% vs. 3%; p < .01) than the latter. Other 
clinical characteristics, such as prior exposure to anthracy-
clines, pattern of metastatic disease, percentage of patients 
receiving trastuzumab-based therapy as first-line therapy 
for metastatic disease, and duration of response to the first 
trastuzumab-containing regimen, were similar between 
the two groups (data not shown).
Discussion
Our retrospective analysis results in HER2-positive 
advanced breast cancer patients progressing during trastu-
zumab-based therapy suggest that clinical outcome was 
similar, regardless of whether trastuzumab was continued 
beyond progression. Three papers reported on retrospec-
tive analyses focusing on patients continuing trastuzumab 
beyond disease progression [9–11]. Those studies included 
patients who had received at least two subsequent trastu-
zumab-based regimens for metastatic disease. Fountzilas 
et al. [10] described the clinical outcome of 80 patients 
continuing trastuzumab beyond disease progression in 
combination with additional chemotherapy. The first post-
progression treatment resulted in a 24% response rate and a 
median progression-free survival duration of 5.2 months, 
but tumor responses were also seen with subsequent trastu-
zumab-based lines of treatment [10]. In a similar retrospec-
tive analysis conducted in 105 patients, Gelmon et al. [9] 
reported a 32% response rate and a median progression-free 
survival of 24–30.5 weeks when either trastuzumab alone or 
combined with chemotherapy was administered as second-
Table 4. Summary of first post-progression treatments: 
patients stopping trastuzumab
Treatment n
Chemotherapy 61
 Vinorelbine 11
 Taxanes (docetaxel or paclitaxel) 9
 CMF-like regimens 9
 Vinorelbine plus 5-FU CI 6
 Anthracycline-based regimens 6
 Vinorelbine plus gemcitabine 5
 Capecitabine 5
 Capecitabine plus cisplatin 4
 Gemcitabine 2
 Other regimens 4
Endocrine therapy 10
 Letrozole 7
 Exemestane 2
 Megestrol acetate 1
Abbreviations: 5-FU, 5-fluorouracil; CI, continuous infu-
sion; CMF, cyclophosphamide, methotrexate, 5-fluorouracil.
Table 5. Summary of clinical outcome beyond progression
Rapidly progressing Continuing trastuzumab Stopping trastuzumab
Clinical outcome variable (n = 21) (n = 40) (n = 71)
RR, %a NE 17.9 (28) 27.3 (66)
95% CI NE 7.9–35.6 18.0–39.0
Median OS, months 7.4 30.1 30.2
95% CI 4.6–10.3 26.9–33.3 20.5–39.9
Median TT-SP, months
NE
6.3 7.2
95% CI 5.0–7.6 6.4–7.9
Median PPS, months 2.4 21.0 18.7
95% CI 1.9–2.9 8.9–33.1 12.3–25.0
aThe numbers in parentheses indicate patients available for response evaluation.
Abbreviations: CI, confidence interval; NE, not evaluable; OS, overall survival; PPS, post-progression survival; RR, response 
rate (complete response plus partial response); TT-SP, time to second progression.
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line treatment after failure of an initial trastuzumab-based 
regimen. The third paper reported the results of a compan-
ion treatment-extension trial of the H0648g pivotal ran-
domized study of chemotherapy alone and chemotherapy 
plus trastuzumab in HER2-positive advanced breast cancer 
patients [1, 11]. This companion study allowed patients in 
the chemotherapy-alone arms to receive trastuzumab upon 
disease progression and patients in the chemotherapy plus 
trastuzumab arms to continue trastuzumab beyond dis-
ease progression. While the primary aim of the companion 
study was to assess the safety of trastuzumab administered 
for long periods of time, the authors also reported efficacy 
results. In 93 patients continuing trastuzumab beyond 
disease progression, the response rate was 11%, and the 
median duration of response was 6.7 months. 
Although all authors placed caution on the interpreta-
tion of these outcomes, their results probably supported the 
practice of continuing trastuzumab beyond progression. 
Indeed, a recent longitudinal cohort study showed that, in 
the U.S., as many as 76% of patients progressing during an 
initial trastuzumab-based regimen received trastuzumab 
plus another chemotherapy in the following line of chemo-
therapy outside clinical trials [14]. 
Our paper and the others that we have discussed above 
share the common limitations of retrospective analyses. 
This approach cannot account for the selection bias that 
goes into individualized therapeutic decisions. For exam-
ple, we found that women who continued trastuzumab 
beyond progression were younger and more likely to have 
achieved tumor response to the initial trastuzumab-con-
taining regimen compared with patients stopping trastu-
zumab upon disease progression. This may reflect dif-
ferent attitudes of physicians toward particular subsets 
of patients, making comparisons between outcomes of 
patients receiving different treatments unreliable. Another 
limitation of our analysis comes from the long half-life of 
trastuzumab once the steady state has been reached [14]. 
As a consequence, even in patients discontinuing trastu-
zumab and receiving different anticancer agents, tumor 
response may still depend on potential additive or syner-
gistic effects of the monoclonal antibody. With these limi-
tations well in mind, however, we believe that our data pro-
vide some valuable information for the clinician, as well 
as implications for further research. First, chemotherapy 
without trastuzumab yielded reassuring results in terms 
of response rate and survival in patients who progressed 
on trastuzumab-based therapy. Breast cancer with HER2 
amplification or overexpression has long been recognized 
as a biologically aggressive disease [15, 16]. Trastuzumab-
based treatments have improved the prognosis for HER2-
positive breast cancer, to the point that it might become 
Figure 2. Kaplan-Meier estimates of overall survival (A), time 
to second progression (B), and post-progression survival (C) 
in patients receiving (dashed line) and not receiving (solid 
line) trastuzumab beyond disease progression.
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better than that of HER2-negative tumors treated with the 
same chemotherapy [17]. It is thus commonly perceived 
that, after trastuzumab failure, HER2-positive metastatic 
breast cancer patients have few options left. However, our 
data show that, with the exception of patients with rapidly 
progressing disease, chemotherapy and endocrine therapy 
were active in a significant proportion of patients, appar-
ently regardless of trastuzumab continuation. Second, 
similar to cytotoxic chemotherapy or endocrine therapy, 
for which progression during treatment denotes “chemo-
resistant” or “endocrine-resistant” disease, tumor pro-
gression during trastuzumab is likely to be sustained by 
specific mechanisms of resistance to this agent. Results of 
the recently completed adjuvant randomized trials [3, 4] 
will translate into a greater number of patients receiving 
trastuzumab as part of the treatment for early HER2-posi-
tive disease. Resistance to this agent will therefore become 
a relevant issue when deciding the therapeutic conduct in 
those patients who develop metastatic disease during or 
shortly after adjuvant treatment with trastuzumab. Unfor-
tunately, despite several interesting hypotheses having 
been generated in preclinical and translational studies [18, 
19], resistance to trastuzumab has not yet been defined 
in patients. Results with lapatinib, a small-molecule dual 
inhibitor of both epidermal growth factor receptor 1 and 
HER2, in heavily pretreated patients with HER2-positive 
advanced breast cancer who had failed prior trastuzumab-
based treatments [20] further confirm that resistance 
to trastuzumab develops in patients and that it could be 
potentially overcome by other targeting agents. 
Third, and not less important, trastuzumab therapy is 
expensive [21]. Outside the use as first-line therapy in appro-
priately selected HER2-positive breast cancer patients, its 
cost-effectiveness is unknown and probably unfavorable. 
 Many authorities in the field of breast cancer have 
invoked appropriately designed randomized trials to define 
the optimal therapeutic approach in women with HER2-
positive advanced breast cancer developing disease pro-
gression while on trastuzumab-based therapy. These trials 
should clarify clinical as well as biological and pharmaeco-
nomic issues. Unfortunately, so far, the few initiatives that 
have been launched have failed to reach their goals because 
of insufficient accrual and possibly also because of patients’ 
and doctors’ biases toward continuing trastuzumab beyond 
progression [22]. At present, we are aware of only two 
active large trials that are randomizing patients progressing 
while on trastuzumab-based therapy to capecitabine alone 
or capecitabine plus trastuzumab [23] and to vinorelbine 
alone or vinorelbine plus trastuzumab [24]. 
Conclusion
In summary, we showed that further lines of chemotherapy 
or endocrine therapy without trastuzumab yielded accept-
able rates of disease control in HER2-positive advanced 
breast cancer patients progressing on trastuzumab-based 
therapy. Our data question the policy of continuing trastu-
zumab beyond disease progression. However, as they were 
generated from retrospective analyses, neither data for nor 
against the continuation of trastuzumab beyond progres-
sion should translate into clinical guidelines at the present 
time. In our opinion, clinicians facing therapeutic decisions 
should consider and discuss with their patients that continu-
ation of trastuzumab beyond disease progression has theo-
retical but unproven efficacy and that disease control can be 
achieved with other anticancer treatments, even discontinu-
ing trastuzumab. Patient expectations should also be taken 
into account, as well as additional costs and rare but poten-
tially severe cardiac trastuzumab-related toxicity. 
Efforts should be focused on completing the accrual of 
the ongoing randomized trials and on planning new initia-
tives in order to establish the correct strategy in this setting 
of patients. 
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